Market Opportunity

A Compelling Market Opportunity

We are seeing a rising tide of cancer cases worldwide.

waves or surges in cancer cases for multiple reasons:
Increased screenings.
unhealthy changes have affected diet, lifestyle, obesity, the environment and our microbiomes.
Cancer may wreak havoc on the human microbiota. The disease strains the immune system, which may allow bad bacteria in the gut to flourish. Antibiotics used to fight infection also may kill good bacteria in the colon. “Antibiotics are like a grenade,” says Zach Breeding, registered and licensed Advanced Clinical Oncology Dietitian at our Philadelphia hospital. “They can destroy so much bacteria in your gut, both good and bad.” To further complicate matters, cancer treatments may lead to a pronounced imbalance of microorganisms, a condition called dysbiosis.
a woman’s smoking, diet, alcohol consumption and obesity during pregnancy may play roles in her child’s future cancer risk.
Major pharmaceutical companies are offering substantial valuation to take over cancer focused drug companies. In December 2023, Pfizer completed a US$43 billion takeover of cancer-focused biotech company Seagen advising that the takeover would enable it to double its oncology platform.
Ironically, learnings from the COVID pandemic can be applied to disease trend analysis, and to develop healthcare solutions to fight the cancer pandemic.

Gaining Traction

Go-AI has assembled an enviable team of professionals with strong industry expertise and experience in AI, oncology, virology, drug development, advanced medical engineering, and clinical studies.

Nanotherapy Plus (currently equally owned by Go-AI and Dr Balaji Panchapakesan) will conduct preclinical and clinical studies either in Australia, Singapore, Hong Kong, and / or South Africa.

These studies will be designed to demonstrate the effectiveness of our patent pending medical engineering technologies of “Liquid Biopsy Tracker“ and “Nanobomb Plus” Immunotherapy Checkpoint Inhibitors against a range of cancer types.

We plan to partner with cancer treatment and research organisations, and pharmaceutical companies involved in immunotherapy drug development and sales.

A Compelling Market Opportunity

Address

Contacts

Links